UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial

Bone (New York, N.Y.), 2003-10, Vol.33 (4), p.522-532

2003

Volltextzugriff (PDF)

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

Neurology, 2011-09, Vol.77 (13), p.1253-1262

2011

Volltextzugriff (PDF)

Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk

Journal of bone and mineral research, 2004-03, Vol.19 (3), p.394-401

2004

Volltextzugriff (PDF)

Prognostic utility of a semiquantitative spinal deformity index

Bone (New York, N.Y.), 2005-08, Vol.37 (2), p.175-179

2005

Volltextzugriff (PDF)

Structural effects of raloxifene on the proximal femur : results from the multiple outcomes of raloxifene evaluation trial

Osteoporosis international, 2006-04, Vol.17 (4), p.575-586

2006

Volltextzugriff (PDF)

Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter setting

Osteoporosis international, 2009-07, Vol.20 (7), p.1199-1205

2009

Volltextzugriff (PDF)

How conservative is Fisher's exact test? A quantitative evaluation of the two-sample comparative binomial trial

Statistics in medicine, 2008-08, Vol.27 (18), p.3598-3611

2008

Volltextzugriff (PDF)

Anti-vertebral fracture efficacy of raloxifene : a meta-analysis

Osteoporosis international, 2006-02, Vol.17 (2), p.313-316

2006

Volltextzugriff (PDF)

Teriparatide Reduces the Fracture Risk Associated with Increasing Number and Severity of Osteoporotic Fractures

The journal of clinical endocrinology and metabolism, 2005-03, Vol.90 (3), p.1583-1587

2005

Volltextzugriff (PDF)

Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover

Bone (New York, N.Y.), 2006-08, Vol.39 (2), p.237-243

2006

Volltextzugriff (PDF)

Sustained viral response following treatment with direct acting antiviral agents for chronic hepatitis C and the risk of hepatocellular carcinoma

Journal of hepatology, 2017, Vol.66 (1), p.S491-S492

2017

Volltextzugriff (PDF)

Sofosbuvir-based all-oral regimens for patients with chronic hepatitis C genotype 2 infection: integrated analysis of eleven clinical studies

Journal of hepatology, 2017, Vol.66 (1), p.S738-S739

2017

Volltextzugriff (PDF)

Effects of Raloxifene on Fracture Severity in Postmenopausal Women with Osteoporosis: Results from the MORE Study

Osteoporosis international, 2002-11, Vol.13 (11), p.907-913

2002

Volltextzugriff (PDF)

Seeing with new eyes: Finding a path to early intervention trials in Alzheimer’s disease

The Journal of nutrition, health & aging, 2010-04, Vol.14 (4), p.306-309

2010

Volltextzugriff (PDF)

Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index

Bone (New York, N.Y.), 2005-08, Vol.37 (2), p.170-174

2005

Volltextzugriff (PDF)

Efficacy and Safety of Raloxifene 60 Milligrams/Day in Postmenopausal Asian Women

The journal of clinical endocrinology and metabolism, 2003-07, Vol.88 (7), p.3130-3136

2003

Volltextzugriff (PDF)

Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate

Journal of bone and mineral research, 2004-05, Vol.19 (5), p.745-751

2004

Volltextzugriff (PDF)

Anti-vertebral fracture efficacy of raloxifene: a meta-analysis

Osteoporosis international, 2006-02, Vol.17 (2), p.313-316

2006

Volltextzugriff (PDF)

FRI-185 - Sustained viral response following treatment with direct acting antiviral agents for chronic hepatitis C and the risk of hepatocellular carcinoma

Journal of hepatology, 2017, Vol.66 (1), p.S491-S492

2017

Volltextzugriff (PDF)

SAT-274 - Sofosbuvir-based all-oral regimens for patients with chronic hepatitis C genotype 2 infection: integrated analysis of eleven clinical studies

Journal of hepatology, 2017, Vol.66 (1), p.S738-S739

2017

Volltextzugriff (PDF)

Responder Analyses from a 78-Week Phase 2 Placebo-Controlled Study of ELND005 (Scyllo-Inositol) in Mild to Moderate (MM) Alzheimer's Disease (AD) (P04.195)

Neurology, 2012-04, Vol.78 (Meeting Abstracts 1), p.P04-P04.195

2012

Volltextzugriff (PDF)

The Effects of ELND005 (Scyllo-Inositol) on Emergence of Neuropsychiatric Symptoms (NPS) in Mild/Moderate Alzheimer's Disease: Results from a 78-Week Phase 2 Study (P04.215)

Neurology, 2012-04, Vol.78 (Meeting Abstracts 1), p.P04-P04.215

2012

Volltextzugriff (PDF)

Responders to ELND005 (Scyllo-Inositol) Demonstrate Clinical and Biomarker Characteristics Consistent with Mild Alzheimer's Disease (AD): Data from a 78-Week Phase 2 Study in Mild to Moderate (M/M) AD (P04.194)

Neurology, 2012-04, Vol.78 (Meeting Abstracts 1), p.P04-P04.194

2012

Volltextzugriff (PDF)

Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women

Osteoporosis international, 2003-10, Vol.14 (10), p.814-822

2003

Volltextzugriff (PDF)

Raloxifene prevents the growth of uterine leiomyomas in premenopausal women

Fertility and sterility, 2004, Vol.81 (1), p.132-136

2004

Volltextzugriff (PDF)

1 – 25 von 129

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(93)
Mit Volltextzugriff
(108)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(65)
Life Sciences & Biomedicine
(46)
Chemistry
(26)
Physical Sciences
(26)
Biological And Medical Sciences
(24)
Humans
(23)
Female
(20)
Medical Sciences
(16)
Middle Aged
(15)
Aged
(14)
Animals
(14)
Endocrinology & Metabolism
(13)
Chemistry, Inorganic & Nuclear
(11)
Fundamental And Applied Biological Sciences. Psychology
(11)
Osteoporosis
(11)
Biochemistry & Molecular Biology
(9)
Chemistry, Multidisciplinary
(9)
Raloxifene Hydrochloride - Therapeutic Use
(8)
Bone Density - Drug Effects
(7)
Diseases Of The Osteoarticular System
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk

Prognostic utility of a semiquantitative spinal deformity index

Structural effects of raloxifene on the proximal femur : results from the multiple outcomes of raloxifene evaluation trial

Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter setting

How conservative is Fisher's exact test? A quantitative evaluation of the two-sample comparative binomial trial

Anti-vertebral fracture efficacy of raloxifene : a meta-analysis

Teriparatide Reduces the Fracture Risk Associated with Increasing Number and Severity of Osteoporotic Fractures

Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover

Sustained viral response following treatment with direct acting antiviral agents for chronic hepatitis C and the risk of hepatocellular carcinoma

Sofosbuvir-based all-oral regimens for patients with chronic hepatitis C genotype 2 infection: integrated analysis of eleven clinical studies

Effects of Raloxifene on Fracture Severity in Postmenopausal Women with Osteoporosis: Results from the MORE Study

Seeing with new eyes: Finding a path to early intervention trials in Alzheimer’s disease

Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index

Efficacy and Safety of Raloxifene 60 Milligrams/Day in Postmenopausal Asian Women

Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate

Anti-vertebral fracture efficacy of raloxifene: a meta-analysis

FRI-185 - Sustained viral response following treatment with direct acting antiviral agents for chronic hepatitis C and the risk of hepatocellular carcinoma

SAT-274 - Sofosbuvir-based all-oral regimens for patients with chronic hepatitis C genotype 2 infection: integrated analysis of eleven clinical studies

Responder Analyses from a 78-Week Phase 2 Placebo-Controlled Study of ELND005 (Scyllo-Inositol) in Mild to Moderate (MM) Alzheimer's Disease (AD) (P04.195)

The Effects of ELND005 (Scyllo-Inositol) on Emergence of Neuropsychiatric Symptoms (NPS) in Mild/Moderate Alzheimer's Disease: Results from a 78-Week Phase 2 Study (P04.215)

Responders to ELND005 (Scyllo-Inositol) Demonstrate Clinical and Biomarker Characteristics Consistent with Mild Alzheimer's Disease (AD): Data from a 78-Week Phase 2 Study in Mild to Moderate (M/M) AD (P04.194)

Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women

Raloxifene prevents the growth of uterine leiomyomas in premenopausal women

Suchergebnisse filtern